Posted by AGORACOM
at 4:36 PM on Monday, April 6th, 2020
SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info
With the current climate of social distancing and uncertainty, it’s no surprise that events have been forced to cancel or postpone left, right, and centre. Despite the disruption caused by the Coronavirus pandemic, some organisers are persevering with their plans – at least for the time being. One of those events is the Europe Canna Expo, set to take place in London in July.
The Europe Canna Expo (ECE) is scheduled to make a return to London for a 2-day event on 26-27 July. Following the success of last year’s Europe CBD expo at the same location, the ECE will aim to bring together over 90 speakers and 125 exhibitors.
The Venue
The ECE is set to make a return to the London ExCel Centre in Canning Town East London. The event was held at the venue in July 2019, with an array of exhibitors and speakers. This year, the Europe Canna Expo is expected to be even bigger. However, uncertainty remains over the event.
The ExCel Centre is currently home to the temporary Nightingale hospital – the improvised care centre for victims of the Coronavirus. It remains unclear when the need for the venue will be over as the UK’s Coronavirus lockdown continues.
Exhibitors and Speakers
However, should the expo go on as planned, attendees will be spoilt for choice with speakers and professionals set to provide insights into the CBD, cannabinoid, and medical cannabis industries. In addition, the event will be present a huge number of exhibitors including a variety of manufacturers and businesses.
Speakers will include international experts showcasing senior-level insights and global scientific research in the CBD, cannabinoid and medical cannabis sectors. Organisers of the event expect that attendees will include consumers and businesses, as well as policymakers and press.
The event will provide an opportunity for global leading brands to showcase their products to thousands of attendees. From CBD drinks and chocolates to medicinal products, the Europe Canna Expo plans to present the most innovative international brands.
Event Schedule
The ECE organisers are yet to release a detailed schedule for the two-day cannabis expo. This may be due to the ongoing uncertainty surrounding the Coronavirus lockdown. For more information and up-to-date announcements, visit the ECE London website.
Posted by AGORACOM
at 9:13 PM on Sunday, April 5th, 2020
Immune Support product line has been received exceptionally well by consumers
The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers
Initial average spend of Cdn$218.40 per customer
VANCOUVER, BC / April 4, 2020 Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company†or “Mota“) is pleased to provide an update on the recent progress that is fueling the increase in sales for products under its First Class CBD brand. The Immune Support product line has been received exceptionally well by consumers since it launched on March 14, 2020 and has been a significant driver of growth in March. The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers with an initial average spend of Cdn$218.40 per customer.
The Company will be launching a new brand, Nature’s Exclusive CBD on April 6, 2020. The new Nature’s Exclusive CBD brand will introduce a line of Immune Support and CBD products with a higher content of CBD. The Company also anticipates releasing March 2020 financial results for First Class CBD in the next few days.
“The month of March has been exceptional, with new customer signups exceeding expectations. We believe this is a testament to our ability to adapt to the fast-paced eCommerce sector and ability to identify upcoming trends in consumer demand. I am very excited with the rapid progress and look forward to releasing March results in the upcoming days,†stated Ryan Hoggan, CEO of the Company.
The initial average spend per customer was translated from US dollar into Canadian dollar using the Bank of Canada average exchange rate of 1.3953 for March 2020.
About Mota Ventures Corp.
Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.
ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP. Ryan Hoggan Chief Executive Officer
For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com
Posted by AGORACOM-JC
at 12:19 PM on Saturday, April 4th, 2020
Immune Support product line has been received exceptionally well by consumers
The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers
Initial average spend of Cdn$218.40 per customer
VANCOUVER, BC / April 4, 2020 Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company” or “Mota“) is pleased to provide an update on the recent progress that is fueling the increase in sales for products under its First Class CBD brand. The Immune Support product line has been received exceptionally well by consumers since it launched on March 14, 2020 and has been a significant driver of growth in March. The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers with an initial average spend of Cdn$218.40 per customer.
The Company will be launching a new brand, Nature’s Exclusive CBD on April 6, 2020. The new Nature’s Exclusive CBD brand will introduce a line of Immune Support and CBD products with a higher content of CBD. The Company also anticipates releasing March 2020 financial results for First Class CBD in the next few days.
“The month of March has been exceptional, with new customer signups exceeding expectations. We believe this is a testament to our ability to adapt to the fast-paced eCommerce sector and ability to identify upcoming trends in consumer demand. I am very excited with the rapid progress and look forward to releasing March results in the upcoming days,” stated Ryan Hoggan, CEO of the Company.
The initial average spend per customer was translated from US dollar into Canadian dollar using the Bank of Canada average exchange rate of 1.3953 for March 2020.
About Mota Ventures Corp.
Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.
ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP. Ryan Hoggan Chief Executive Officer
For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the anticipated launch of products under the First Class CBD brand, the financial results of First Class CBD, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Posted by AGORACOM
at 1:27 PM on Friday, April 3rd, 2020
RECENT HIGHLIGHTS
Immune Support Product Line Launched on March 14, 2020 Acquired over 5,500 new customers seeking natural solutions to help support their family’s immune systems, yielding an average initial order value of $189.00 USD.
First Class CBD brand achieved sales of Cdn$2,981,000 February 2020
Marketing efforts improved gross margins by 4.9% from January 2020 to February 2020.
February 2020 revenue represents an increase of 832% over the same period last year.
Plans to continue growth of First Class in the United States over the balance of 2020, as well as an expansion into the European market.
Formalized Joint Venture With Bevcanna Enterprises: Read More
Will share equal ownership in the Joint Venture and will be jointly responsible for developing and funding its operations
Company will provide manufacturing, marketing and distribution infrastructure in the European market.
Parties have determined an initial product launch and will provide further details on specific regions and timing once finalized
Formalized Collaboration for Sativida US Expansion Read MoreÂ
Acquired the intellectual property and trade names of Sativida
Unified Funding will provide assistance to Sativida with product sourcing, packaging, shipping, payment infrastructure and marketing
Sativida has become the number one search-ranked online retailer of CBD products in Spain and Mexico
Entered into Licensing Agreement with Phenome One Read More
A privately held full-service live genetic and seed preservation cannabis company.
Mota will have full access to Canada’s largest live genetic cannabis library with over 350 cultivars
Mota will have the right to propagate, cultivate, harvest and process a minimum of 10 selected cultivars
2 World Class Brands:
#1. FIRST CLASS CBD: ONE OF THE LARGEST US BASED ONLINE RETAILERS OF CBD PRODUCTS
HIGHLIGHTS:
Leader in online CBD sales in North America
Crop to package model: US grown CBD hemp
Acquired at a 1.5 times revenue valuation
Current customer base 142,000 customers -with additional leads of over 424,000 potential new customers
2019 Sales of $19.2M USD/ EBITDA of 2.7M USD
#2. SATIVIDA: ONLINE DIRECT TO CONSUMER RETAILER OF A VAST RANGE OF ORGANICE CBD OILS AND COSMETICS
HIGHLIGHTS:
Current distributor of CBD products in Spain, Portugal, Austria, Germany, France and the United Kingdom
Number one search-ranked online retailer in Spain and Mexico
Award winning product line known for its minimal heavy metal content and accurate CBD levels
100% organic products
About Mota Ventures Corp.
Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value added products from its Latin American operations and distribute it both domestically and internationally. Mota has established distribution networks through the acquisition of First Class CBD in the United States and Sativida in Europe. Mota Ventures is also seeking to acquire revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.
Posted by AGORACOM-JC
at 9:21 AM on Monday, March 30th, 2020
At a time when established Cannabis stocks are struggling due to an inability to actually deliver real businesses, Hollister Biosciences (HOLL:CSE) has been quietly building a real business, products, revenue and customers in 220 of California’s 600 dispensaries …. and growing, including California’s #1 hash infused pre-roll “Hashbone”. Â
If that was all Hollister had going, they’d be in great shape with a super bright future and better than most Cannabis companies (small and large) who can’t even get product out the door. Â
BUT THERE’S MORE – THE $20,000,000 ACQUISITION THAT COMES WITH $CDN 16.4M REVENUE & $CDN 2.48M EBITDA Â
Hollister has closed their purchase of Venom Extracts, one of Arizona’s largest producers of Award-Winning Medical Cannabis Distillate. Just how good is Venom? In 2019, Venom generated $CDN 16.4M in revenue and $CDN 2.48M EBITDA in 2019 … and all of that was just from the state of Arizona. Â
In this amazing interview, Venom Founder Jake Cohen discusses Venom’s aggressive plans to expand its brand and success into other states, including California as it benefits from Hollister’s distribution into 220 dispensaries. Right now, some of you may be thinking, “yeah but everybody thinks they are going to expand” …. but Jake’s words, as well as those of Alex Somjen (President) and Carl Saling (CEO) are backed up by action.  Â
Specifically, a significant chunk of Venom’s acquisition shares kicks in if/when revenues hit $CDN 30,000 and $CDN 40,000 …. by December 31, 2021. In my experience, companies joining forces don’t include such terms if there isn’t a reasonable expectation for hitting those numbers. It doesn’t guarantee it but you can bet they have good reason to believe Venom sales will get to one or both of those numbers in just 21 months from now. Â
If you’re looking for Cannabis companies that are going to survive and thrive over this next decade, then grab your favourite beverage and watch this great interview with Carl Saling, Alex Somjen and Jacob Cohen.
Posted by AGORACOM-JC
at 7:18 AM on Monday, March 30th, 2020
This highly accretive acquisition strengthens Hollister’s brand portfolio and broadens its distribution footprint across multiple states positioning Hollister to transform into an industry leader in 2020 and beyond
Venom Extracts reports having generated over CDN$16.4 million in revenue and over CDN$2.5 million in EBITDA from its product line of cannabis concentrates and cartridges.Â
VANCOUVER, March 30, 2020Â –Hollister Biosciences Inc.(CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“), a diversified cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce that further to the signing of the definitive agreement, as amended (the “SEA“), the Company has now closed its transformational acquisition of Venom Extracts (“Venom Extracts“), a leading Arizona cannabis extract brand and one of the state’s largest producers of award-winning medical cannabis distillate and related products (the “Transaction“).
HIGHLY ACCRETIVE $20,000,000 ACQUISITION, ADDING OVER CDN$16.4 MILLION OF 2019 REVENUE
For the year ended December 31, 2019, management of Venom Extracts reports having generated over CDN$16.4 million in revenue and over CDN$2.5 million
in EBITDA from its product line of cannabis concentrates and
cartridges. Venom Extract’s management also reports a strong start to
2020 and is anticipating record Q1 revenue.
The all-stock purchase price of approximately CDN$20,000,000
represents a transaction multiple of 1.2x 2019 revenue, with
approximately 70% of the consideration paid upfront and the
approximately 30% balance to be paid upon milestone achievements related
to revenue targets for Venom Extracts, or in any event, on December 31, 2021. After conducting normal course due diligence, the Transaction closed effective March 24, 2020 (the “Closing Date“).
KEY TERMS OF THE TRANSACTION:
Pursuant to the terms of the SEA, the Company has acquired Venom Extracts for consideration of CDN$20,000,145.20 which is to be satisfied by the issuance of 70,390,672 Hollister common shares (the “Payment Shares“) on the Closing Date pro rata to the shareholders of Venom Extracts and an additional 29,610,054 common shares (the “Earn-Out Shares“)
to certain former shareholders of Venom Extracts on the earlier of (i)
Venom Extracts reaching certain revenue milestones (detailed below), or
(ii) December 31, 2021.
The Payment Shares and the Earn-Out Shares will be issued at a deemed value of CDN$0.20 per share;
The Payment Shares are subject to certain voluntary hold periods
with 90% of the Payment Shares being subject to hold periods as follows:
15% until May 25, 2020; and an additional 15% every six months until November 25, 2022;
The Earn-Out Shares will be issued on the earlier of (i) December 31, 2021, or (ii) when and if the following milestones have been met:
19,740,036 Earn-Out Shares will be issued when revenue of Venom Extracts reaches CDN$30,000,000 (calculated in accordance with IFRS from January 1, 2020); and
An additional 9,870,018 Earn-Out Shares will be issued when revenue of Venom Extracts reaches CDN$40,000,000 (calculated in accordance with IFRS from January 1, 2020).
“We are extremely pleased to complete this transformational and highly accretive acquisition”, shared Carl Saling, Founder and CEO of Hollister Biosciences Inc. “Our acquisition of Venom Extracts bolts on substantial revenue and EBITDA to Hollister, while providing Venom Extracts the ability to expand its offering of premium branded product into the California marketplace. Likewise, our acquisition also allows Hollister to introduce its products into the Arizona and Nevada marketplaces through Venom Extracts’ existing distribution channels.”
“This is an exciting acquisition and we are very pleased to announce closing”, shared Jacob Cohen, Founder of Venom Extracts. “This transaction represents the next step in ensuring the future growth of both Hollister and Venom Extracts. We are looking forward to increasing our geographic presence by expanding into the California marketplace through Hollister’s existing platform, and exploring expansion of our existing product portfolio collectively.”
In association with the acquisition, Hollister will not
be assuming any long-term debt, a new control position will be created
and there is no change in management, or the board of directors of Hollister being contemplated at this time.
In connection with the Transaction, the Company issued 6,000,000 common shares (the “Finder Shares“) to an arm’s length third party finder at a deemed price of $0.20
per Finder Share. The Finder Shares are subject to a statutory hold
period of four months and a day from the Closing Date which expires July 25, 2020.
This press release is available on the Company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
None of the securities to be issued pursuant to the Transaction have
been or will be registered under the U.S. Securities Act of 1933, as
amended (the “U.S. Securities Act“), or any state
securities laws, and any securities issued pursuant to the Transaction
are anticipated to be issued in reliance upon available exemptions from
such registration requirements pursuant to Rule 506(b) of Regulation D
and/or Section 4(a)(2) of the U.S. Securities Act and applicable
exemptions under state securities laws. In addition, the securities
issued under an exemption from the registration requirements of the U.S.
Securities Act will be “restricted securities” as defined under Rule
144(a)(3) of the U.S. Securities Act and will contain the appropriate
restrictive legend as required under the U.S. Securities Act.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a diversified cannabis company with
multiple, high-quality products now carried in 220 of Indus Holdings
(CSE: INDS), Hollister’s exclusive
distribution partner’s 600 dispensaries. This level of penetration is
expected to grow as the Company accelerates its seed to shelf, high
margin business and product development model.
Capitalizing on this success, Hollister’s vision is to
become the sought-after premium brand portfolio of innovative, high
quality cannabis across multiple states and hemp products nationwide.
Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California,
the birthplace of the “American Biker” from which we embrace the outlaw
roots of Hollister to drive our Company fearlessly down the road of
success.
Products from Hollister Cannabis Co. include HashBone, the brand’s
premier artisanal hash-infused pre-roll ranked as California’s #1 hash
infused pre-roll, along with solvent-free bubble hash, pre-packaged
flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD
pet tinctures.
Venom Extracts is one of Arizona’s premier extract
brands and one of the state’s largest producers of award-winning medical
cannabis distillate and related products. With an experienced
management team and unparalleled reputation for quality, Venom Extracts
prides itself as a differentiated extraction company by producing legal
Marijuana products at a price point that allows retailers to generate
higher profits. Focused on proprietary efficiencies, the Company is
able to produce more product per square foot than its competition,
maintaining lower costs and risks than a typical extraction company. The
company’s expansion strategy is centered on entering new markets/states
that are approved for medical cannabis use and/or approved or have a
reasonable expectation to be approved for recreational use in the near
future.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release includes certain
statements that may be deemed “forward-looking statements”. The use of
any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”,
“will”, “would”, “project”, “should”, “believe” and similar expressions
are intended to identify forward-looking statements. Although the
Company believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance
should not be placed on the forward-looking statements because the
Company can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by
their very nature they involve inherent risks and uncertainties. These
statements speak only as of the date of this News Release. Actual
results could differ materially from those currently anticipated due to a
number of factors and risks including various risk factors discussed in
the Company’s disclosure documents which can be found under the
Company’s profile on www.sedar.com.
Tags: Cannabis, CBD, CSE, Hemp, Marijuana, stocks, tactical relief, tsx Posted in Featured, Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca Closes Transformational Acquisition of Rapidly Growing Venom Extracts Adding Over $16.4 Million In 2019 Revenue and $2.5 Million in EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca
Posted by AGORACOM
at 5:06 PM on Friday, March 27th, 2020
Since March 14, 2020, Mota has acquired over 5,500 new customers
The product has yielded an average initial order value of $189.00 USD.
Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the “Company” or “Mota“) is pleased to announce that since the launch of its Immune Support product line on March 14, 2020, the Company has acquired over 5,500 new customers seeking natural solutions to help support their family’s immune systems. The popularity of the primary product has yielded an average initial order value for immune support customers of $189.00 USD. Earlier this week the Company introduced an Immune CBD oil and Elderberry Gummies. The new Immune CBD product contains CBD, B3, B12, vitamin C and zinc and is made from 100% pure essential oils containing cinnamon leaf, lemon, clove bud, lime, eucalyptus, globulus, rosemary, peppermint, spearmint and oregano.
The Company has acquired over
50,000 new customer inquiries for Immune Support/CBD products since
March 14, 2020. The Immune Support line is gaining interest from
customers that historically were hesitant to purchase CBD, but are now
interested in the Immune products and the potential anti-inflammatory
benefits of CBD. In addition, traditional brick-and-mortar stores have
been affected due to social distancing requirements, driving consumers
to purchase online from the safety of their homes.
“The Immune
Support product launch has been the most successful product launch in
the history of our First Class brand. E-Commerce is a fast-moving
sector, especially during these very unique times we are facing today.
Our ability as a company to quickly develop and launch new products to
meet market demand is a testament to our expertise. I am very excited by
the reception we have received to date for our Immune Line of products.
I project demand for the line will continue through Q2 and be a
significant driver to our growth for 2020,” stated Ryan Hoggan, CEO of
the Company.
Additionally, the Company has entered into a 12 month
programmatic digital advertising campaign with Native Ads, Inc. for a
total cost of C$80,000; consisting of C$72,000 for digital advertising,
paid distribution, and media buying over the campaign period and,
C$8,000 for content creation, consulting, managed services and
management fees over the course of the campaign period. Native Ads is a
full-service advertising agency, that owns and operates a proprietary ad
exchange with over 80 integrated SSPs (supply side platforms) resulting
in access to 3-7 billion daily North American ad impressions. Neither
Native Ads nor any of its directors and officers own any securities of
the Company.
About Mota Ventures Corp.
Mota is
seeking to become a vertically integrated global CBD brand. Its plan is
to cultivate and extract CBD into high-quality value-added products from
its Latin American operations and distribute it both domestically and
internationally. Its existing operations in Colombia consist of a
2.5-hectare site that has optimal year-round growing conditions and
access to all necessary infrastructure. Mota is looking to establish
sales channels and a distribution network internationally through the
acquisition of the Sativida and First Class CBD brands. Low cost
production, coupled with international, direct to customer sales
channels will provide the foundation for the success of Mota.
ON BEHALF OF THE BOARD OF DIRECTORS MOTA VENTURES CORP.
Ryan Hoggan Chief Executive Officer
For
further information, readers are encouraged to contact the President of
the Company, Joel Shacker, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com
Posted by AGORACOM-JC
at 9:31 AM on Thursday, March 26th, 2020
SPONSOR: NORTHBUD (NBUD:CSE)
Sustainable low cost, high quality cannabinoid production and
procurement focusing on both bio-pharmaceutical development and
Cannabinoid Infused Products. The company recently received Canadian
Cultivation Licence for its Quebec Facility. Learn More.
Posted by AGORACOM
at 8:51 AM on Thursday, March 26th, 2020
Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the “Company” or “Mota“)
is pleased to announce that further to its January 10, 2020 news
release, it has now acquired the intellectual property and trade names
of Sativida from Sativida OU (Estonia). The Company will license both
back to Sativida OU’s subsidiary, VIDA BCN LABS S.L. (collectively with
Sativida OU, “Sativida“) in exchange for a royalty associated with the gross revenues generated by Sativida.
Sativida is an arms’-length producer and online retailer of cannabidiol (“CBD“)
and branded CBD products in various jurisdictions in Europe, including
Spain, Portugal, Austria, Germany, France and the United Kingdom.
Sativida currently develops and retails a vast range of organic CBD oils
and cosmetics across Europe and is in the process of expanding its
distribution network internationally to include the United States.
Sativida has become the number one search-ranked online retailer of CBD
products in Spain and Mexico, and intends to continue its expansion into
other countries in Europe and Latin America.
Through Mota, Sativida has an agreement with Unified Funding, LLC (“Unified“)
for the expansion of the brand into the United States. Unified will
provide assistance to Sativida with product sourcing, packaging,
shipping, payment infrastructure and marketing in the United States.
Unified Funding is an e-Commerce and technology company focused on
serving U.S.-based and international consumers in the CBD and natural
health products market. Powered by its proprietary technology platform,
Unified has created an e-Commerce ecosystem to scale its brands through
data analysis, strategic customer acquisition and supply chain
management. Since June 2015, Unified has generated a database of over
4.5 million consumers and has facilitated over US$200 million in
consumer transactions from more than one million paying customers.
“I
am very excited to announce the acquisition of the Sativida brand. This
gives Mota immediate entry into the European market and will be a
building block for our planned European expansion. Mota’s U.S.
operation, First Class CBD, is set to enter the European market and we
expect the acquisition of the Sativida brand to expedite this expansion.
Furthermore, our partnership with Unified Funding, LLC, the e-Commerce
platform behind the success of First Class CBD, will allow us to bring
the Sativida brand to the U.S. market as well,” stated Ryan Hoggan, CEO
of the Company.
Noah
Laith, founder of Sativida, commented, “Joining Mota is a major step
for Sativida that will provide access to the capital, connections and
infrastructure necessary to grow our business in Europe and
internationally.”
Pursuant to the previously announced binding agreement with Sativida dated January 9, 2020 (the “Transaction Agreement“), the Company was granted the right to acquire Sativida in stages (the “Transaction“),
at the discretion of the Company, as certain corporate and intellectual
property registrations were completed. To accomplish this, the Company
set up a wholly-owned Spanish subsidiary (“Spanish Subco“)
and coordinated the registration of various intellectual property and
trade names associated with business operations of Sativida.
The
Company, through Spanish Subco, has now completed the acquisition of
the intellectual property and trade names of Sativida in Spain, and will
license both back to Sativida in exchange for a royalty associated with
the gross revenues generated by Sativida. Pursuant to the Transaction
Agreement, the Company also holds the right to acquire, through Spanish
Subco, all of the outstanding share capital of Sativida at any time for
no additional consideration.
Consideration for the Transaction is made up of an initial component of €2,000,001 (the “Consideration“) and an earn-out component made up of three milestone payments based upon the revenue of Sativida (each, a “Milestone Payment“). The Consideration was paid in 5,496,221 common shares of the Company (the “Consideration Shares“)
at a deemed price of $0.5689 per share. Each Milestone Payment will be
based on a 400% multiple of Sativida’s revenue until the aggregate of
the Initial Consideration and Milestone Payments reaches €4,000,000, at
which point the multiple will be reduced to 100%. In no event will the
combined Milestone Payments and the value of the Initial Consideration
exceed €15,000,000. Payment of the Milestone Payments will be satisfied
by the Company issuing common shares (“Milestone Shares“)
to Sativida. The total number of Milestone Shares issuable to Sativida
will be determined by dividing the amount due by the volume weighted
average closing price of the Company’s common shares on the Canadian
Securities Exchange in the ten trading days prior to the day that the
Milestone Payment is due.
The
Consideration Shares and the Milestone Shares will each be subject to a
36-month pooling arrangement such that 10% of the Consideration Shares,
or the Milestone Shares, as applicable, will be released from escrow on
upon their issuance, with an additional 15% being released every
six-months thereafter until all Consideration Shares or all Milestone
Shares, as applicable, are released.
As
part of the Transaction, Mota Ventures will enter into employment
contracts with certain employees of Sativida and will provide an option
pool that may be divided among the employees of Sativida equal to
€60,000 in stock options of Mota Ventures for every €1,000,000 in
revenue that Sativida earns, subject to certain conditions.
Additionally, Mota Ventures has paid a 10% finder’s fee based on the
total value of the Consideration Shares (528,072 common shares) to
certain finders that assisted in introducing the Transaction to the
parties as well as a 2% administrative success fee based on the total
value of the Consideration Shares (105,614 common shares) to a
consultant who assisted in the administration of the transaction.
The
Company and Sativida are at arms’-length. The Transaction is not
expected to result in a “reverse-takeover” or “fundamental change” for
the Company under the policies of the Canadian Securities Exchange, or
result in the creation of any new insider or control person of the
Company. No changes to the board of directors, or management, of the
Company are contemplated in connection with the Transaction.
About Mota Ventures Corp.
Mota
is seeking to become a vertically integrated global CBD brand. Its plan
is to cultivate and extract CBD into high-quality value-added products
from its Latin American operations and distribute it both domestically
and internationally. Its existing operations in Colombia consist of a
2.5-hectare site that has optimal year-round growing conditions and
access to all necessary infrastructure. Mota is looking to establish
sales channels and a distribution network internationally through the
acquisition of the Sativida and First Class CBD brands. Low cost
production, coupled with international, direct to customer sales
channels will provide the foundation for the success of Mota.
About Sativida
Sativida
is a producer and online retailer of CBD and branded CBD products in
various jurisdictions in Europe, including Spain and the United Kingdom.
Sativida currently develops and retails a vast range of organic CBD
oils and cosmetics across Europe and is currently expanding its
distribution network internationally. For more information on Sativida,
readers are encouraged to review their website at www.sativida.es.
ON BEHALF OF THE BOARD OF DIRECTORS MOTA VENTURES CORP.
Ryan Hoggan Chief Executive Officer
For
further information, readers are encouraged to contact the President of
the Company, Joel Shacker, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com
Posted by AGORACOM-JC
at 7:36 AM on Tuesday, March 24th, 2020
In the wake of the COVID-19 pandemic, Hollister is using its essential business standing and facility to source and produce hand sanitizer for its local community.
The CEO of Hollister Biosciences Inc, Carl Saling, shared: “The community of Hollister, CA is near and dear to our hearts, and as the first licensed cannabis company in the city of Hollister, CA, I feel that we must do whatever we can to help.
VANCOUVER, March 24, 2020 –Hollister Biosciences Inc.(CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – through its Hollister Cannabis Co division, is stepping up to manufacture and distribute a few thousand bottles of hand sanitizer to Hollister, CA.
A statewide “shelter at home” mandate has been issued for California,
putting a halt to non-essential manufacturing and delay in
distribution. Cannabis retailers and manufacturers are considered
essential businesses in California. In the wake of the COVID-19 pandemic, Hollister is using its essential business standing and facility to source and produce hand sanitizer for its local community.
Hollister will be giving its first batch of hand sanitizer to the Hollister food bank. Multiple batches of hand sanitizer are expected to be delivered to community organizations over the next few weeks.
The CEO of Hollister Biosciences Inc, Carl Saling, shared: “The community of Hollister, CA is near and dear to our hearts, and as the first licensed cannabis company in the city of Hollister, CA, I feel that we must do whatever we can to help.
It infuriated me seeing companies price gouging much needed items,
such as hand sanitizer. I am all for making money, but not at the
expense of playing on people’s fears during a time of crisis. We just
had to act.
We are going to focus on donating to the facilities that are often
overlooked: the food bank, nursing homes, rehabilitation centers, and
homeless shelters, where some of the most vulnerable are sheltering in
place.
I am calling all business owners to step up in this time of crisis and do whatever you can to help your local community.”
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a California based
vertically integrated cannabis company with a vision to be the
sought-after premium brand portfolio of innovative, high-quality California-grown cannabis and hemp products. Hollister
uses a vertically integrated, high margin model, controlling the whole
process from manufacture to sales to distribution or seed to shelf.
Products from Hollister Cannabis Co. include HashBone, the brand’s
premier artisanal hash-infused pre-roll, along with solvent-free bubble
hash, pre-packaged flower, pre-rolls, tinctures, vape products, and
full-spectrum high CBD pet tinctures. Hollister Cannabis Co.
additionally offers white-labeling manufacturing of cannabis products.
Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker.”
Neither the Canadian Securities Exchange nor its Market Regulator
(as that term is defined in the policies of the Canadian Securities
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-Looking Information: This news release includes certain
statements that may be deemed “forward-looking statements”. The use of
any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”,
“will”, “would”, “project”, “should”, “believe” and similar expressions
are intended to identify forward-looking statements. Although the
Company believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance
should not be placed on the forward-looking statements because the
Company can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by
their very nature they involve inherent risks and uncertainties. These
statements speak only as of the date of this News Release. Actual
results could differ materially from those currently anticipated due to a
number of factors and risks including various risk factors discussed in
the Company’s disclosure documents which can be found under the
Company’s profile onwww.sedar.com
